Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 02, 2015 3:04 AM ET

Biotechnology

Company Overview of NeuroGenetic Pharmaceuticals, Inc.

Company Overview

NeuroGenetic Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drug therapies for use in the prevention and treatment of neurodegenerative disorders. It focuses on Alzheimer’s disease (AD) therapeutics. The company offers a patented technology of gamma-secretase modulators that alters the production of amyloid proteins from the toxic form found in AD brains to non-toxic forms, which do not contribute to plaque deposition. It has patents in the United States, India, China, Canada, Mexico, and internationally. The company was founded in 2009 and is based in Del Mar, California.

445 Marine View Avenue

Suite 101

Del Mar, CA 92014

United States

Founded in 2009

Phone:

858-461-4480

Fax:

858-461-4485

Key Executives for NeuroGenetic Pharmaceuticals, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 79
Co-Founder
Age: 57
Director of Finance
Senior Director of Development
Compensation as of Fiscal Year 2015.

NeuroGenetic Pharmaceuticals, Inc. Key Developments

NeuroGenetic Pharmaceuticals, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 11:00 AM

NeuroGenetic Pharmaceuticals, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 11:00 AM. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

The U.S. Food and Drug Administration Approves NeuroGenetic Pharmaceuticals, Inc. Application to Begin Clinical Trials for its NGP 555

The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application from NeuroGenetic Pharmaceuticals, Inc. (NGP) to begin clinical trials on its NGP 555 compound to treat and prevent Alzheimer's disease (AD). The approval follows successful completion of all preclinical phases under a fast-track grant from the National Institute of Neurologic Disease and Stroke (NINDS). NGP 555, a proprietary "first in class" molecule for the treatment/prevention of Alzheimer's disease, is a gamma-secretase modulator (GSM) demonstrating good brain penetration and targeting the gamma-secretase complex, a key enzyme in the amyloid pathway.

NeuroGenetic Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-26-2014 09:45 AM

NeuroGenetic Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-26-2014 09:45 AM. Venue: San Diego Convention Center, San Diego, California, United States.

Similar Private Companies By Industry

Company Name Region
Nortis Inc. United States
Reata Pharmaceuticals, Inc. United States
ImmunePath, Inc. United States
Biomerk, Inc. United States
VacTex, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
February 25, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NeuroGenetic Pharmaceuticals, Inc., please visit www.neurogeneticpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.